Myśliwiec J, Kretowski A, Szelachowska M, Mikita A, Kinalska I
Department of Endocrinology, Medical Academy of Białystok, Poland.
Rocz Akad Med Bialymst. 1999;44:160-9.
The aim of the study was to estimate serum pro-inflammatory cytokines concentration: TNF alpha and IL-6 as well as anti-inflammatory cytokine levels: IL-10 and IL-1ra in patients with Graves' disease and ophthalmopathy before and during glucocorticoid therapy. Serum cytokines were detected in three groups of subjects: 20 patients with Graves' disease without ophthalmopathy (GD), 17 patients with clinical symptoms of ophthalmopathy (GO) (CAS > or = 3, anamnesis of GO > or = 1 yr) and 24 healthy volunteers. Glucocorticoid therapy consisted of intravenous infusions of methyloprednisolone (MP) (2 series, 3 grams each time) and subsequent treatment with oral prednisone (60 mg per day) in a tapering schedule. The serum samples were collected 24 hours before MP, 24 hours after MP, 12 +/- 2 days of treatment with prednisone and at the end of glucocorticoid therapy. The levels of TNF alpha, IL-6, IL-10 and IL-1ra in the serum were determined by the ELISA method. The statistical significance was estimated by the Mann-Whitney U-test. Serum IL-6 level was increased in patients with GO in comparison to the controls and did not change significantly after immunosuppressive treatment. We did not find any significant differences of serum TNF alpha between the studied groups and glucocorticoids did not change its level significantly. Serum IL-10 was elevated significantly both in patients with GD and GO in comparison to the control group. IL-10 levels increased significantly after glucocorticoids. IL-1ra level was significantly higher in patients with GO. In the GO group we found an increase of IL-1ra after MP treatment and its gradual decline during prednisone therapy.
本研究旨在评估糖皮质激素治疗前及治疗期间格雷夫斯病(GD)合并眼病患者血清促炎细胞因子浓度:肿瘤坏死因子α(TNFα)和白细胞介素-6(IL-6)以及抗炎细胞因子水平:白细胞介素-10(IL-10)和白细胞介素-1受体拮抗剂(IL-1ra)。在三组受试者中检测血清细胞因子:20例无眼病的格雷夫斯病患者(GD组)、17例有眼病临床症状的患者(GO组)(临床活动评分(CAS)≥3,眼病既往史≥1年)和24名健康志愿者。糖皮质激素治疗包括静脉输注甲泼尼龙(MP)(2个疗程,每次3克),随后口服泼尼松(每天60毫克)并逐渐减量。在MP治疗前24小时、MP治疗后24小时、泼尼松治疗12±2天以及糖皮质激素治疗结束时采集血清样本。采用酶联免疫吸附测定(ELISA)法测定血清中TNFα、IL-6、IL-10和IL-1ra的水平。采用曼-惠特尼U检验评估统计学意义。与对照组相比,GO组患者血清IL-6水平升高,免疫抑制治疗后无明显变化。我们未发现研究组之间血清TNFα有任何显著差异,糖皮质激素也未使其水平发生显著变化。与对照组相比,GD组和GO组患者血清IL-10均显著升高。糖皮质激素治疗后IL-10水平显著升高。GO组患者IL-1ra水平显著更高。在GO组中,我们发现MP治疗后IL-1ra升高,泼尼松治疗期间逐渐下降。
1.浸润性格雷夫斯眼病中促炎和抗炎细胞因子的产生均增加。2.有效的糖皮质激素治疗可能与其对抗炎细胞因子IL-10和IL-1ra的影响有关。